Combinations ;
1. Cyproterone / Ethinylestradiol
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Androcur | Bayer Schering Pharma | Bayer East Africa Ltd. | 50mg | 20 | Tablet | per tablet | KES 2,886.12 |
| Cyproplex | Teva Pharmaceuticals | Kulal International Ltd. | 50mg | 50 | Tablet | per tablet | KES 2,049 |
| Cyproterone acetate More info | |
|---|---|
| Mode Of Action | Cyproterone is a synthetic progestogen, which is an androgen inhibitor that also suppresses gonadotrophin secretion. |
| Drug Indication | Prostatic cancer (advanced) and suppression of GnRH analogue related initial tumour flare, hot flushes related to orchidectomy or GnRH therapy, Male hypersexuality |
| Precautions | |
| Contra-Indications | Do not apply in prostate cancer, severe diabetes (with vascular changes), sickle-cell anaemia, liver-disease including Dubin-Johnson and Rotor syndromes, previous or existing liver tumours, malignant or wasting diseases, meningioma or history of meningioma, severe depression, history of thromboembolic disorders; youths under 18 years (may arrest bone maturation and testicular development). |
| Side Effects | Fatigue; thrombosis (coronary and venous) hypertension; depression; change in libido and fertility; diarrhea; allergic reactions; altered cognitive functions; reduced adrenal functions; oedema; altered carbohydrate metabolism. |
| Dosage | Prostatic cancer (advanced) and suppression of GnRH analogue-related initial tumour flare: 100mg BD or TID. Hot flushes related to orchidectomy or GnRH therapy: 100mg OD (reduced to 50mg OD or on the alternate days. Male hypersexuality: 50mg BD. |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Steroid hormones and related synthetic drugs |
| 1. Cyproterone / Ethinylestradiol | |
|---|---|
| Mode Of Action | Cyproterone is a synthetic progestogen, which is an androgen inhibitor that also suppresses gonadotrophin secretion. |
| Drug Indication | Severe acne refractory to prolonged antibacterial therapy, mild to moderate idiopathic hirsutism, androgen dependent alopecia, and as oral contraceptives. |
| Precautions | Diabetes, hypertension, asthma, depression, risk of thrombosis, fluid retention, amenorrrhoea, oligomenorrhoea, rule out any clotting system disturbances, epilepsy, tetany, varicose veins. |
| Contra-Indications | Pregnancy and lactation, thromboembolism, undiagnosed vaginal bleeding, tumours, history of herpes, itching, jaundice of pregnancy |
| Side Effects | Prolonged amenorrhoea, nausea and vomiting, thrombosis (coronary and venous) hypertension, cardiovascular accidents, weight gain, vaginal candidiasis, fluid retention, hepatic tumours, change in libido. |
| Dosage | 1 OD x 21 days from day 1 of menstrual cycle. Repeated after a 7-day interval, usually for months |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Steroid hormones and related synthetic drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Diane- | Bayer Schering Pharma | Bayer East Africa Ltd. | 2mg/50mg | 21 | Tablet | per tablet | KES 921.8 |
| Giane- | Renata Limited | Harley's Limited | 2mg/50mg | 21 | Tablet | per tablet | KES 650 |
| Diane-35 | Bayer Schering Pharma | Bayer East Africa Ltd. | 2mg/50mg | 21 | Tablet | per tablet | KES 1,035.76 |
| Giane-35 | Renata Limited | Unisel Pharma (K) Ltd. | 2mg/50mg | 21 | Tablet | per tablet | KES 650.00 |